Novo Nordisk settles case of market manipulation, will pay USD 100m

Novo Nordisk and former executives Lars Rebien Sørensen, Jesper Brandgaard and Jakob Riis have reached a settlement in the lawsuit involving alleged market manipulation between 2015 and 2016.

Photo: Niels Hougaard/ERH

A US class action litigation, which since 2017 has been hanging over Novo Nordisk and its three former executives, Lars Rebien Sørensen, Jesper Brandgaard and Jakob Riis, now seems to have reached its conclusion, the company reports in a press release.

The company writes that an agreement to settle has been reached in the case concerning alleged violations of the US securities laws. The plaintiffs, shareholders of Novo Nordisk, claimed that the company and aforementioned executives were guilty of market manipulation back in 2015 and 2016, when company share price took a significant dip over a long period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs